VECTURA
Vectura Limited
Trademark Registered: 2017-04-04
Trademark Application Details
REGISTERED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 86698312 |
| Registration Number | 5174039 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Mark Harrison |
| Attorney Docket Number | 38618-388698 |
| Law Office Assigned | N20 |
| Employee Name | JOHNSON, DANYTHE ELIZA |
Timeline
| 2015-07-20 | Application Filed |
| 2017-01-17 | Published for Opposition |
| 2017-04-04 | Location: PUBLICATION AND ISSUE SECTION |
| 2017-04-04 | Status: Live/Registered |
| 2017-04-04 | Trademark Registered |
| 2018-07-08 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  Vectura Limited |
| Entity Statement | limited company (ltd.) |
| Address | 1 Prospect West Chippenham, Wiltsh GB SN146FH |
| Legal Entity Type | |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| International Codes: | 10 |
| U.S. Codes: | 026,039,044 |
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system; pharmaceutical and veterinary preparations for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and veterinary preparations for the alleviation or prevention of pain or inflammation; inhalers filled with powders for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical preparations, namely, powders for asthma inhalers; pharmaceutical preparations, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and veterinary preparations for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; medicaments for inhalation therapy; pharmaceutical preparations, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; medicaments for the treatment of erectile dysfunction; medicaments for the treatment of chronic obstructive pulmonary disease; medicaments for the treatment of premature ejaculation; medicaments for the treatment of cystic fibrosis; medicaments for the treatment of female sexual dysfunction; medicaments for the treatment of migraines; medicaments for the treatment of asthma; all of the above goods not for use in the dental field |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2015-07-23 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2015-07-24 | 2 NWOS I:Incoming Correspondence |
| TEAS VOLUNTARY AMENDMENT RECEIVED | 2015-09-21 | 3 PARI I:Incoming Correspondence |
| ASSIGNED TO LIE | 2015-10-09 | 4 ALIE A:Allowance for Publication |
| APPLICANT AMENDMENT PRIOR TO EXAMINATION - ENTERED | 2015-10-19 | 5 AMPX O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2015-10-29 | 6 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2015-11-05 | 7 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2015-11-05 | 8 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2015-11-05 | 9 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2016-05-02 | 10 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-05-04 | 11 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-05-04 | 12 TEME I:Incoming Correspondence |
| NON-FINAL ACTION WRITTEN | 2016-05-25 | 13 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2016-05-25 | 14 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2016-05-25 | 15 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2016-11-17 | 16 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-11-17 | 17 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-11-17 | 18 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2016-11-28 | 19 CNSA O:Outgoing Correspondence |
| LAW OFFICE PUBLICATION REVIEW COMPLETED | 2016-12-12 | 20 PREV O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2016-12-28 | 21 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2017-01-17 | 22 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2017-01-17 | 23 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2017-04-04 | 24 R.PR A:Allowance for Publication |
| COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | 2022-04-04 | 25 REM1 E:E-Mail |
| CANCELLED SEC. 8 (6-YR) | 2023-10-20 | 26 C8.. O:Outgoing Correspondence |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 